Zurzuvae (zuranolone) is a prescription drug that’s used to treat postpartum depression. The drug comes as a capsule that you swallow. It’s usually taken once per day for 14 days. Zurzuvae is used in ...

Biogen has received an NOC from Health Canada for Zurzuvae, a NAS, as a treatment for moderate or severe PPD in women.

ZURZUVAE ™ is a neuroactive steroid (NAS) that acts as a positive allosteric modulator of GABA-A receptors, enhancing inhibitory signalling in the brain. The GABA system is the major inhibitory ...

PHILADELPHIA (WPVI) -- Last month, Zurzuvae, the first oral pill approved in the United States to treat postpartum depression, became available. Local mental health care providers say this novelty ...

Zurzuvae (zuranolone) can cause side effects that range from mild to serious. More common side effects include dizziness and diarrhea. If side effects from Zurzuvae become difficult to tolerate, talk ...

Zurzuvae, the recently FDA-approved pill to treat postpartum depression. (Image: Getty; illustration by Alex Cochran for Yahoo) In August the Food and Drug Administration approved Zurzuvae (zuranolone ...

ZURZUVAE, the first and only oral, once-daily, 14-day treatment course, has shown to provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3 for women with PPD Patient ...

The first oral pill approved in the United States to treat postpartum depression is now available by prescription, according to the drugmakers. The US Food and Drug Administration approved the therapy ...

Postpartum depression (PPD) approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE rapidly improved symptoms of PPD at Day 15 and as early as Day 3 ...